This section presents medications that are known to potentially lead to 'Corneal epithelium defect' as a side effect. It's important to note that mild side effects are quite common with medications.

The approval and commercialization of Oxervate (cenegermin-bkbj, Dompé) in the United States has improved our ability to treat corneal persistent epithelial defects (PEDs) or corneal ...

Credit: Thinkstock. KPI-012 is a topically dosed ophthalmic therapy designed using the Company's human mesenchymal stem cell secretome platform. The Food and Drug Administration (FDA) has granted ...

KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and ...

The central four fifths of the left cornea is denuded of epithelium (arrows indicate the margins of the defect), and there is diffuse stromal edema with infiltrates inferonasally. The patient was ...

Corneal epithelial defects were either stable or improved, with patients 1, 2, and 3 achieving grade 0 (no defect) by week 52, while patient 4 remained at grade 1. All patients reported either ...

About KPI-012 for Persistent Corneal Epithelial Defect (PCED) Based on a multifactorial mechanism of action and preclinical and clinical data generated to-date, Kala believes KPI-012 may represent ...

application for KPI-012 for the treatment of persistent corneal epithelial defect. What Happened: The FDA accepted Kala's IND application for its lead product candidate, KPI-012 ...

The IND of KPI-012 for the treatment of patients with persistent corneal epithelial defect (PCED) was accepted by the FDA on December 27, 2022. KPI-012 was developed using Kala Pharmaceuticals ...